Customizing the therapeutic response of signaling networks to promote antitumor responses by drug combinations.

Alexey Goltsov¹, Simon P Langdon², Gregory Goltsov³, David J Harrison⁴, James Bown¹

¹Centre for Research in Informatics and Systems Pathology (CRISP), University of Abertay Dundee , Dundee , UK.

²Division of Pathology, Institute of Genetics and Molecular Medicine, Western General Hospital, University of Edinburgh , Edinburgh , UK.

³Touch Surgery , London , UK.

⁴School of Medicine, University of St Andrews , St Andrews , UK.

PubMed PMC DOI PDF

Abstract

Drug resistance, de novo and acquired, pervades cellular signaling networks (SNs) from one signaling motif to another as a result of cancer progression and/or drug intervention. This resistance is one of the key determinants of efficacy in targeted anti-cancer drug therapy. Although poorly understood, drug resistance is already being addressed in combination therapy by selecting drug targets where…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.